PMC7649792_01
Computed tomography scan or magnetic resonance imaging scan before (A,C,E) and after (B,D,F) low-dose decitabine combined with camrelizumab therapy in these 3 cases. Tumor lesions are indicated by red arrows.
fonc-10-558572-g0001.jpg
PMC7649792_03_fonc-10-558572-g0001.jpg
F1
April 2017, a CT scan revealed that metastatic lesions in the liver increased significantly (Figure 1E) and thus the patient was administered low-dose decitabine (10 mg/day, days 1-5) plus camrelizumab (200 mg, day 6) every 3 weeks for 8 cycles. After 2 cycles of treatment, abdominal magnetic resonance imaging revealed a reduction in the lesions of the liver lobe (Figure 1F).
PMC7649792_02
Computed tomography scan or magnetic resonance imaging scan before (A,C,E) and after (B,D,F) low-dose decitabine combined with camrelizumab therapy in these 3 cases. Tumor lesions are indicated by red arrows.
fonc-10-558572-g0001.jpg
PMC7649792_03_fonc-10-558572-g0001.jpg
F1
April 2017, a CT scan revealed that metastatic lesions in the liver increased significantly (Figure 1E) and thus the patient was administered low-dose decitabine (10 mg/day, days 1-5) plus camrelizumab (200 mg, day 6) every 3 weeks for 8 cycles. After 2 cycles of treatment, abdominal magnetic resonance imaging revealed a reduction in the lesions of the liver lobe (Figure 1F).
PMC7649792_03
Computed tomography scan or magnetic resonance imaging scan before (A,C,E) and after (B,D,F) low-dose decitabine combined with camrelizumab therapy in these 3 cases. Tumor lesions are indicated by red arrows.
fonc-10-558572-g0001.jpg
PMC7649792_03_fonc-10-558572-g0001.jpg
F1
April 2017, a CT scan revealed that metastatic lesions in the liver increased significantly (Figure 1E) and thus the patient was administered low-dose decitabine (10 mg/day, days 1-5) plus camrelizumab (200 mg, day 6) every 3 weeks for 8 cycles. After 2 cycles of treatment, abdominal magnetic resonance imaging revealed a reduction in the lesions of the liver lobe (Figure 1F).
The treatment timeline of the three patients.
fonc-10-558572-g0002.jpg
PMC7649792_03_fonc-10-558572-g0002.jpg
F2
Tissue DNA HDQ 96 Kit, Agilent Technologies) of tumor biopsies before and after combination therapy are shown in Table 1 A figure of the treatment timeline of the three patients is revealed in Figure 2. The expression of